Everlab Raises $65M Series A for AI-Powered Longevity Health

Melbourne-based preventative health innovator, Everlab, has successfully closed a $65 million Series A funding round, signaling significant investor confidence in its AI-driven approach to proactive wellness. The substantial capital infusion was spearheaded by Airtree Ventures, with crucial participation from prominent international firms including Plural, b2venture, and existing backer Left Lane Capital. The round also saw backing from a notable list of angel investors, including Australian cricket captain Pat Cummins, underscoring the broad appeal of Everlab's mission.

This latest funding marks a rapid ascent for the three-year-old company, which has already analyzed over 20,000 individuals across Australia and New Zealand. Everlab leverages advanced biomarker diagnostics and artificial intelligence to provide personalized health insights, aiming to detect and mitigate potential health issues before they manifest. The company's platform integrates a comprehensive suite of services, including diagnostics, physician coordination, specialist referrals, prescription management, and continuous AI-powered health monitoring, all accessible through a unified digital application.

The strategic deployment of these funds is earmarked for aggressive expansion, most notably a significant push into the United Kingdom market. Beyond geographical growth, Everlab plans to bolster its clinical and technological infrastructure, further enhancing its diagnostic capabilities and AI algorithms. The company's existing operational scale is impressive, with its platform integrating with over 1,850 health provider locations, engaging more than 180 active clinicians, and supporting over 30 wearable devices, processing in excess of 200,000 health reports monthly.

Everlab's model has already demonstrated tangible impact, with over 25% of its clients identified as having previously undetected health concerns through its rigorous testing protocols. This success has led to adoption by major corporate entities, including Boston Consulting Group, BHP, and Bain & Company, for their executive health programs. The company offers a tiered service structure, with basic health assessments starting at $299, and more comprehensive packages, including genetic testing and MRI scans, ranging up to $3,499.

The preventative health sector is experiencing robust growth, driven by increasing consumer awareness of wellness and the potential of technology to deliver more personalized and effective healthcare solutions. The global digital health market is projected to reach hundreds of billions of dollars in the coming years, with AI and diagnostics playing a pivotal role. Everlab's focus on early detection and integrated care positions it favorably within this expanding market, addressing the fragmentation often found in traditional healthcare systems.

Marc Hermann, Everlab's co-founder and CEO, who previously co-founded the successful Foodspring brand before its acquisition by Mars, highlighted the company's vision. "We built Everlab to hold the full picture, surface health blind spots and coordinate what needs to happen next—from targeted screenings to personalised health plans—helping more people live longer, healthier lives," Hermann stated. This Series A funding, with its strong international investor base including Airtree Ventures, Plural, b2venture, and Left Lane Capital, alongside other supporters like Afterwork Ventures, Ten13, Flying Fox, and Temedica, provides Everlab with the resources to execute this ambitious vision on a global scale.